Quarterly ResultMay 12, 2026, 07:47 AM
Xilio Therapeutics Q1 Net Loss Narrows to $9.5M; Revenue Jumps to $12.6M
AI Summary
Xilio Therapeutics reported a narrowed net loss of $9.5 million for the first quarter of 2026, a significant improvement from the $13.3 million loss in the prior year. This was driven by a substantial increase in collaboration and license revenue, which reached $12.6 million. The company maintains a strong liquidity position with $150.3 million in cash and cash equivalents, projected to fund operations for at least the next twelve months, and anticipates further proceeds from warrant exercises.
Key Highlights
- Net loss for Q1 2026 narrowed to $9.5 million, an improvement from $13.3 million in Q1 2025.
- Collaboration and license revenue significantly increased to $12.6 million in Q1 2026 from $2.9 million in Q1 2025.
- Research and development expenses rose to $19.8 million in Q1 2026, up from $8.3 million in Q1 2025.
- Cash and cash equivalents stood at $150.3 million as of March 31, 2026.
- Company anticipates existing cash will fund operations for at least 12 months from the filing date.
- Received $57.0 million in payments from AbbVie collaboration as of March 31, 2026.
- Potential to receive up to $36.2 million from Series C common stock warrant exercises in H2 2026.
Price Impact
More from XLO